RESTON, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axonius Federal Systems LLC (AFS), the asset intelligence platform for unified security operations and exposure management for the public sector, today announced the appointment of Jared Vichengrad as senior vice president and general manager. Reporting directly to the AFS Board of Directors, Vichengrad will lead the company’s dedicated federal organization, overseeing strategy, execution, and growth across the U.S. federal market. Vichengrad brings more than 2 ...

Core Insights - Celldex announced multiple presentations of Phase 2 clinical trials for barzolvolimab at the 2026 AAAAI Annual Meeting, focusing on chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) [1][2] Group 1: Clinical Trial Presentations - New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented, indicating that retreatment with barzolvolimab results in rapid improvement in urticaria control after symptom recurrence [2] - The presentations include: - **Phase 2 ColdU and SD Study**: "Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria" on February 27, 2026 [2] - **Phase 2 CSU Study**: "Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria" on February 27, 2026 [2] - **Phase 2 ColdU and SD Study**: "Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria" on March 1, 2026 [2] Group 2: Barzolvolimab Overview - Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action targeting mast cells by binding to a unique part of the KIT receptor, which is critical for mast cell function and survival [3] - The drug shows significant potential as a first-in-class treatment for CSU, ColdU, and SD, based on data from robust Phase 2 studies [3] - Barzolvolimab is currently undergoing Phase 3 studies for CSU and ColdU/SD, as well as Phase 2 studies for prurigo nodularis (PN) and atopic dermatitis (AD) [3] Group 3: Company Background - Celldex is focused on pioneering new therapies in immunology, particularly antibody-based treatments that engage the human immune system to address allergic, inflammatory, and autoimmune disorders [4]

Meddelelse nr. 04/2026: Registrering af kapitalforhøjelse og opdaterede vedtægter February 23, 2026 08:00 ET  | Source: Strategic Investments A/S Strategic Investments A/S ...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a f ...

Atlanta, GA., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace for firearms, hunting and related products, today announced that it has entered into a settlement agreement with Innovative Computer Professionals, Inc., d/b/a Digital Cash Processing (“DCP”), resolving the previously disclosed litigation pending in the United States District Court for the District of Minnesota. ...

ALBUQUERQUE, N.M., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology and fixed-tilt products, foundation solutions, software systems and services, today announced that members of its senior management team are scheduled to participate in the following conference for the investor community. Jefferies Power, Energy, Clean Energy, and Utilities ConferenceAttendees: Kevin Hostetler, CEO and Investor Relati ...

Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data a ...

Core Viewpoint - Kratos Defense & Security Solutions and GE Aerospace have secured a $12.4 million contract with the U.S. Air Force to design the GEK1500 engine, aimed at enhancing performance and reducing costs for small Collaborative Combat Aircraft (CCA) [1][2]. Group 1: Contract and Engine Development - The contract focuses on completing the preliminary design of the GEK1500 engine, which is expected to meet high performance and cost targets [1]. - The GEK1500 engine is designed to provide 1,500 lbs of thrust and is intended for use in unmanned aerial systems, collaborative combat aircraft, and missiles [3]. - The development of the GEK1500 builds on the successful GEK800 engine program, utilizing lessons learned to improve thrust, power generation, and lifecycle costs [2][4]. Group 2: Strategic Collaboration - The partnership between Kratos and GE Aerospace is formalized through a teaming agreement that aims to advance propulsion technologies for affordable unmanned aerial systems and CCA-type aircraft [5]. - This collaboration enhances the companies' existing relationship and is based on a 2024 Memorandum of Understanding to develop cost-effective engines for unmanned platforms [5]. Group 3: Technological Advancements - Recent altitude testing of the GEK800 engine has demonstrated critical technologies that will enhance the performance of future systems, including increased range and decreased lifecycle costs [4]. - The GEK1500 engine design leverages the successful architecture of the GEK800 cruise missile engine, which is currently undergoing technical maturation [3]. Group 4: Company Backgrounds - Kratos has over 25 years of experience in developing small, affordable engines for UAS, drones, and missile platforms, while GE Aerospace brings a century of expertise in propulsion technology [7]. - GE Aerospace operates with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines, emphasizing its leadership in aerospace propulsion [8].

Company Overview - ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering at-risk patients and their caregivers to protect against allergic reactions that could lead to anaphylaxis [3] Upcoming Events - The company will host a conference call and webcast on March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights [1] - ARS Pharma Management will participate in several upcoming investor conferences, including the 10th Annual Oppenheimer Emerging Growth Conference on February 25, 2026, and the Leerink Conference on March 11, 2026 [4] Product Information - ARS Pharmaceuticals is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and pediatric patients aged 4 years and older who weigh 33 lbs. or greater in the U.S. [3] - In the EU, neffy® is indicated for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adults and children who weigh 30 kg or greater [3]

Core Viewpoint - Daré Bioscience has received FDA clearance for its investigational drug DARE-HPV, which aims to treat persistent high-risk HPV infections, marking a significant advancement in women's health as there are currently no FDA-approved pharmacologic treatments for HPV [1][5][8] Company Overview - Daré Bioscience is a health biotech company focused on addressing gaps in women's health through innovative solutions backed by rigorous research [9][10] - The company aims to provide evidence-based therapies for various women's health issues, including HPV infections, which have historically lacked effective treatment options [10] Product Development - DARE-HPV is a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infections, which are responsible for nearly all cervical cancer cases in the U.S. [2][3][8] - The drug targets the virus directly, potentially redefining the treatment paradigm for cervical disease prevention by intervening before precancerous changes occur [2][5] Clinical Study and Funding - The planned Phase 2 clinical study will evaluate the safety and antiviral activity of DARE-HPV in women with persistent high-risk HPV infection, supported by a $10 million contract from the Advanced Research Projects Agency for Health (ARPA-H) [5][6] - The company has received $6.5 million of the funding to date and is preparing to initiate the study in 2026 [5][6] Market Need - Persistent high-risk HPV infection represents a substantial unmet medical need, as current standard care involves monitoring without treating the virus, leading to significant physical and emotional burdens for women [4][6] - The lack of effective treatments has resulted in women being subjected to costly and burdensome "watchful waiting" visits, contributing to disparities in cervical cancer outcomes [5][6]